Abstract
In March 2020, Coronavirus Disease 2019 originating from Wuhan, China, has become pandemic. Based on epidemic data from China we constructed and constrained a simple Susceptible–Infected– Infectious–Excluded (SIIE) model. The model is characterized by only three parameters: average incubation period, contact rate rC, and exclusion rate rE. These two rates control the daily multiplication coefficient β describing epidemic growth in its early exponential phase, during which the number of excluded (confirmed) individuals grows as E = E0 exp(α t) with α = ln β. The rates can be modified by non-therapeutic interventions: rC can be reduced by quarantine, while rE can be increased by efficient testing, enabling isolation of infectious individuals. In order to contain exponential epidemic growth, quotient rC/rE has to be reduced to 1. Based on the model, we estimate that the quarantine imposed in China on January 23, 2020 resulted in about 50-fold reduction of this quotient, allowing to terminate the exponential growth phase and enter the phase of exponential regression of daily new cases. In contrast, quarantine imposed in northern, most affected, Italian provinces on February 21 resulted in about 3-fold reduction of rC/rE and corresponding decrease of β from about 1.5 to about 1.2; further 5-fold reduction is necessary to terminate exponential growth. Even higher reduction should take place in France, Germany and Spain for which β > 1.3 (as of March 10, 2020). Considering longer-term dynamics in the case when the initial exponential growth is not contained by quarantine, we analyzed a scenario in which rE decreases in response to the surge of daily new cases which convinces people to isolate themselves. In such case, initial abrupt epidemic growth is followed by a slow decrease over years. This scenario, although economically and socially devastating, grants time to develop, produce, and distribute vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Science Centre (Poland) grant 2018/29/B/NZ2/00668
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data referred in the manuscript are available at JHU CSSE, https://systems.jhu.edu/research/ public-health/ncov, accessed: 2020-03-11 and https://www.worldometers.info/coronavirus/ covid-19-testing, accessed: 2020-03-12